Literature DB >> 23109296

Chemotherapy and cognitive complaints in women with breast cancer.

Marleen J J Pullens1, Jolanda De Vries, Laurence J C Van Warmerdam, Marieke A Van De Wal, Jan A Roukema.   

Abstract

BACKGROUND: Results of existing studies are inconclusive concerning the relationship between chemotherapy and subjective cognitive functioning (SCF). The aim of this study was to evaluate SCF of breast cancer (BC) patients and to find predictors of impaired SCF. Both satisfaction and frequency of complaints about SCF were measured.
METHODS: BC patients who were about to receive chemotherapy (N = 74) and patients with a benign breast disease (BBD) (N = 63) participated. Before chemotherapy started (Time 1) and 3 months after ending chemotherapy (and at comparable moments for the BBD group) (Time 2), women completed validated questionnaires concerning the frequency of complaints and satisfaction with SCF, fatigue, perceived stress, anxiety, and depressive symptoms.
RESULTS: No differences were found between the BBD and BC patients concerning the frequency of complaints about SCF across time. Satisfaction with SCF decreased across time in BC patients but remained stable across time in BBD patients (p < 0.001; p = 0.003 after controlling for state anxiety and perceived stress). Correlation coefficients between the satisfaction and the frequency of complaints about SCF ranged between -0.26 and -0.49. Depressive symptoms and satisfaction with SCF (Time 1) predicted the frequency of complaints about SCF (Time 2). Diagnosis, frequency of complaints about SCF, and state anxiety (Time 1) predicted satisfaction with SCF (Time 2).
CONCLUSIONS: BC patients do not differ in the frequency of complaints about SCF compared with BBD patients, but their satisfaction with SCF decreased after treatment. Psychological factors predicted the frequency of complaints about SCF. Psychological factors and diagnosis predicted satisfaction with SCF.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Keywords:  breast cancer; cancer; chemotherapy; cognitive complaints; oncology; subjective cognitive functioning

Mesh:

Substances:

Year:  2012        PMID: 23109296     DOI: 10.1002/pon.3214

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  16 in total

1.  Impact of increasing physical activity on cognitive functioning in breast cancer survivors: Rationale and study design of Memory & Motion.

Authors:  Sheri J Hartman; Loki Natarajan; Barton W Palmer; Barbara Parker; Ruth E Patterson; Dorothy D Sears
Journal:  Contemp Clin Trials       Date:  2015-09-30       Impact factor: 2.226

Review 2.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

3.  The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients.

Authors:  Huaidong Cheng; Wen Li; Chen Gan; Bo Zhang; Qianqian Jia; Kai Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

4.  A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON).

Authors:  Laura Tack; Tessa Lefebvre; Michelle Lycke; Chistine Langenaeken; Christel Fontaine; Marleen Borms; Marianne Hanssens; Christel Knops; Kathleen Meryck; Tom Boterberg; Hans Pottel; Patricia Schofield; Philip R Debruyne
Journal:  EClinicalMedicine       Date:  2021-08-19

5.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

Review 6.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

7.  Cognitive function in patients prior to undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park
Journal:  Support Care Cancer       Date:  2020-08-23       Impact factor: 3.603

8.  Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer.

Authors:  A Amidi; S Christensen; M Mehlsen; A B Jensen; A D Pedersen; R Zachariae
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

9.  Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study.

Authors:  Ryosuke Kitahata; Shinichiro Nakajima; Hiroyuki Uchida; Tetsu Hayashida; Maiko Takahashi; Shintaro Nio; Jinichi Hirano; Maki Nagaoka; Takefumi Suzuki; Hiromitsu Jinno; Yuko Kitagawa; Masaru Mimura
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-03       Impact factor: 2.570

10.  Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors.

Authors:  Huaidong Cheng; Wen Li; Liang Gong; Han Xuan; Zhonglian Huang; Hong Zhao; Long Sheng Wang; Kai Wang
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.